Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	2.5	1.56	1.54	1.01
Research & Development	2.23	6.27	2.81	2.77
Total Operating Expenses	4.73	7.82	4.35	3.78
Operating Income	-4.73	-7.82	-4.35	-3.78
Total Non-Operating Income (Expense)	-1.75	-1.16	-26	0
Pretax Income	-6.48	-8.99	-30.36	-3.78
Net Income	-6.48	-8.99	-30.36	-3.78
Net Income to Common	-6.48	-8.99	-30.36	-3.78
Shares Outstanding (Basic)	46	45	34	11
Shares Outstanding (Diluted)	46	45	34	11
Shares Change (YoY)	17.90%	32.81%	219.94%	-
EPS (Basic)	-0.15	-0.20	-0.89	-0.35
EPS (Diluted)	-0.15	-0.20	-0.89	-0.35
Free Cash Flow	-5.3	-3.94	-2.57	-0.17
Free Cash Flow Per Share	-0.11	-0.09	-0.08	-0.02
EBITDA	-4.73	-7.82	-4.35	-3.78
EBIT	-4.73	-7.82	-4.35	-3.78

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 15, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error